Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
milatuzumab + doxorubicin
- Development stage
- Discontinued
- Lead developer
- Gilead Sciences
- Modality
- Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Milatuzumab + doxorubicin is an antibody-drug conjugate (ADC) consisting of the humanized anti-CD74 monoclonal antibody milatuzumab linked to the cytotoxic agent doxorubicin. Milatuzumab targets CD74, a cell surface protein highly expressed in multiple myeloma and certain lymphoid malignancies, and facilitates targeted delivery of doxorubicin to malignant cells, thereby enhancing cytotoxic efficacy and minimizing off-target toxicity. Mechanistically, milatuzumab blocks CD74 signaling, interrupts pro-survival pathways (e.g., PI3K/Akt, NF-κB), induces apoptosis, and mediates immune functions such as antibody-dependent cellular cytotoxicity (ADCC). Clinical and preclinical studies have shown milatuzumab-doxorubicin to produce anti-tumor effects in multiple myeloma and lymphoma, but clinical development was ultimately discontinued due to limited efficacy[2][4][5][7][8][9].
- Brand names
- IMMU-110IMMU110IMMU 110
- Other names
- milatuzumab-doxorubicinmilatuzumab–doxorubicin conjugate
02
Targets
TOP2A (DNA topoisomerase II)CD74 (Major histocompatibility complex class II invariant chain)
Beyond the preview
Go deeper on milatuzumab + doxorubicin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on milatuzumab + doxorubicin.